DIRECTORY
BIOTECH
Pharmaclient

   

Quick Click ! Monthly news Home-Site Menu-Site Contactexpress Faqs Legends Companies Events Environment Memories Home-Biotech

Abcys | AB Science | Adocia | Advicenne Pharma | Affichem | Agate Bioservices | Aisa Therapeutics | Alfact Innovation | Alizé Pharma | Ambiotis | Anaconda Pharma | Aptys Pharmaceuticals | Ariana Pharmaceuticals | Aterovax | Atlantic Bone Screen | Aureus Sciences | B Cell Design | BioAlliance Pharma | Biocortech | BioCydex | Biométhodes | Biom'up | BioProtein Technologies | BioQuanta | BioSystems International | BMSystems (Bio-Modeling) | Carmat | Cellectis | Cellial Technologies | CellProthera | CellVax | Cerenis Therapeutics | CliniGenetics | Covalab | Cytheris | Cytoo | DBV Technologies | Diaxonhit | DNA Therapeutics | Domain Therapeutics | Dynabio | Edelris | Endotis Pharma | Epixis | ERYtech Pharma | Eye Tech Care | Flamel Technologies | Fluofarma | GemacBio | Genepep | Genewave | Genfit | Genomic Vision | GenoSafe | GenoScience Pharma | Genoscreen | GenOway | Genticel | GTP Technology | Helios Biosciences | Hemarina | Hybrigenics | Hyphen BioMed | Imagene | ImmunId | Immutep | Imstar | In-Cell-Art | Indicia Biotechnology | InGen Biosciences | Innate Pharma | InnaVirVax | Innovative Health Diagnostics | IntegraGen | Ipsogen | I-Stem | Karcinolys | Keosys | MABlife | Magnisense | Mapreg | Mauna Kea Technologies | Medesis Pharma | Mellitech | Metabolys | MilleGen | Murigenetics | NanoBiotix | Neorphys | Neovacs | Netris-Pharma | Neuronax | NewVectys | NicOx | Nokad | Nosopharm | NovAliX | NovoCIB | Novotec | Obe Therapy | Oligovax | Oncodesign | OriBase Pharma | Oroxcell | Oxincell | Palumed | PharmaLeads | Pharnext | PhenoPro | Pherecydes Pharma | PolyIntell | Proteogenix | Protexel | PX'Therapeutics | Quantum Genomics | Rhenovia Pharma | ScarCell Therapeutics | Sisène Biotechnologies | Skuld-Tech | Stentys | Synapcell | Synprosis | Tc Land Expression | Theraclion | Theradiag | Theralpha | TheraVectys | Transgene | Trophos | TxCell | UROsphere | Vaxon Biotech | Vectalys | Vivalis | XenTech |

* INNATE PHARMA *


 

1999 - Méditerranée
Marseille
www.innate-pharma.com

 

Discovery, Drugs
Key words: Immuno-therapy, Immuno-modulators, Toll-like receptors (TLR), Cancer, IPH 4201
Mission: to develop first in class drugs targeting the innate immune system
Clients: Prescribers
info@innate-pharma.fr

Age: 17 year(s)

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Start-up |
Managing Dir.-CEO: Brailly (Hervé) [co-founder, born 1961, Ph.D., ex-Immunotech-Beckman-Coulter]
Sc.Dir.-CSO: Romagné (François) [Ph.D., co-founder, ex-Immunotech-Beckman-Coulter]
Clin.Dir.-CMO: Rozencweig (Marcel) [M.D., ex-BMS]
Fin.Dir.-CFO: Moukheibir (Catherine) [MBA, ex-Zeltia, Shire, Movetis]
BusDev: Morel (Yannis) [Ph.D. oncology, NormalSup]
Financers (Hist.): Sofinnova Partners, Auriga Partners, GIMV, Alta Partners, Gilde Biotech & Nutrition, Pechel Industries, Innoveris, Quilvest, NIF Ventures, Novo-Nordisk, Public

Turnover (M€) : 3.7 (2009), 8.7 (2007), 6.2 (2006)
Total funding (M€) : 125.3
Last funding (M€) : 23.1
Focus : Cancers
Position : Clinical
Company confirm : none

 

History
DATEMILESTONETYPETIME
2012 .10 Clinical trial (phase II, beginning) for monoclonal antibody IPH 2102, supported by Bristol Myers Squibb (with BMS-986015 as an anti-KIR antibody in combination with an anti-PD1 antibody in patients with advanced solid tumors) CLIN [13 years]
2012 .01 Research : publication in Science of discovery in the field of innate immunity, made by a team led by Prof. Eric Vivier, Innate Pharma's scientific co-founder at the Center of Immunology of Marseille-Luminy (CIML) R&D [12 years]
2011 .07 Licensing-out to Bristol-Myers Squibb of of IPH2102, a novel antibody in Phase I development for the treatment of cancer (upfront payment of 35 MUS$ plus milestones up to 430 MUS$) LICOUT [11 years]
2011 .05 Partnering development agreement with Transgene for immunomonitoring services, with set-up of new company named Platine Pharma Services R&D [11 years]
2009 .12 5th round-financing : 23.1 M€, by FSI (for 11 M€) and previous investors (Novo Nordisk and Alta Partners) RFINE [10 years]
2009 .09 Clinical trial (phase II) for IPH1101 in smoldering myeloma (beginning) CLIN [10 years]
2009 .08 Clinical trial (phase II, beginning) for monoclonal antibody IPH 2101, supported by 2.9 M€ financing from Oseo (results published in October 2012) CLIN [9 years]
2009 .06 Clinical trial (phase IIa, positive) for IPH1101 in type C Hepatitis CLIN [9 years]
2009 .05 Launch of Platine, a joint immuno-monitoring platform, by 5 partners (Innate Pharma, Transgene, ImmunID, Inserm and Cancer Centre Léon-Bérard), based in Lyon MKTG [9 years]
2009 .01 Partnering research agreement with Vivalis to produce IPH 4101 with EB66 for clinical trials (Oseo debt financing grant of 3.0 M€ for Innate Pharma) R&D [9 years]
2008 .04 Set-up of US subsidiary (operations) in New York State ORGC [8 years]
2008 .02 Set-up of 2 subsidiaries (trade, production) in France ORGC [8 years]
2007 .05 Nomination : Gilles Brisson, new Board Chairman, ex-Chairman Supervisory Board at Aventis Pharma France ORGN [7 years]
2007 .01 Launch of PGX Predict (diagnostics) by Clinical Data Inc., US partner MKTG [7 years]
2006 .11 Listing on Eurolist by Euronext Paris : 33.7 M€ PBO [7 years]
2006 .00 4th round-financing : 10.0 M€, by Novo Nordisk RFIND [6 years]
2006 .06 Licensing-in of lead compound (TLR) from Schering-Plough LICIN [6 years]
2006 .03 Licensing-out to Novo Nordisk (total of 15.0 M€ equity investment, including 2003 deal) LICOUT [6 years]
2004 .07 3nd round-financing : 15.0 M€, by Novo Nordisk, Quilvest and NIF Ventures RFINC [4 years]
2003 .11 Licensing-out to Novo Nordisk for the generation of a new therapeutic class of immuno-modulatory antibodies targeting natural killer (NK) cells LICOUT [4 years]
2002 .08 2nd round-financing : 20.0 M€, by Alta Partners and AXA P.E., with Gilde Biotech & Nutrition, Pechel Industries, Innoveris RFINB [2 years]
2002 .05 Clinical trial (phase I) for Innacell and Phosphotim (beginning) CLIN [2 years]
2002 .02 Financing (no interest loan) : 2.0 M€, by ANVAR, to support initial clinical trials DEBT [2 years]
2000 .04 1st round-financing : 4.5 M€, led by Sofinnova Partners, with Auriga Partners, GIMV RFINA [0 year]
1999 .10 Company founded by 4 European Scientists, pioneers in the field of innate immunity (Alessandro Moretta, Marc Bonneville, Jean-Jacques Fournier and Eric Vivier) and 2 managers from the biopharmaceutical industry (Hervé Brailly and François Romagné) ORGF [0 year]

Actualisation / Updating: 14-Nov-2012

   


Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT



© J.H. Huber, Pharmaclient 2001-2017. Pour retourner à la page d'accueil Biotech: BIENVENUE !       Haut de page : légende